Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315036 | 0.82 | IDO1 (0.46) | ALDH1A1CYP2D6BACE1 | |
| SCHEMBL2027168 | 0.81 | LOXL2 (0.41) | LOXL2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12855670 | 0.80 | AGXT (0.52) | CYP1A2RAB9A | |
| SCHEMBL15489965 | 0.80 | TDP1 (0.37) | ALDH1A1RAB9ABACE1DUT | |
| SCHEMBL906834 | 0.80 | IDO1 (0.48) | CYP3A4HSD17B10BACE1 | |
| SCHEMBL3426875 | 0.78 | AGXT (0.32) | CYP3A4BACE1DUT | |
| SCHEMBL3178345 | 0.78 | PPARG (0.40) | ALDH1A1BACE1DUT | |
| SCHEMBL133816 | 0.78 | MAOB (0.39) | LOXL2CYP3A4ALDH1A1RAB9ACYP19A1 | |
| SCHEMBL7262934 | 0.78 | AGXT (0.32) | BACE1DUT | |
| SCHEMBL481257 | 0.78 | IDO1 (0.50) | ALDH1A1RAB9ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727940-A1 | DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | Linkcure Therapeutics (KY) | 2026-04-22 | — | — | EP | disclosed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| WO-2024255810-A1 | DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| WO-2024051631-A1 | MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州朗睿生物医药有限公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117659043-A | Macrocyclic imidazo [1,2-b ] pyridazine derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| WO-1997012876-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997005878-A1 | 2,5-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | disclosed |
| WO-1997005877-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5217963-A | Antiischemic, antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-5057506-A | Anticonvulsants, antispasmodic and antischemic agents | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| US-4906621-A | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0275820-A2 | Unsaturated phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | LOXL2 218/4885CYP1A2 1046/4885CYP3A4 1727/4885 |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | LOXL2 218/4885CYP1A2 1046/4885CYP3A4 1727/4885 |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | LOXL2 1713/4885CYP1A2 268/4885CYP3A4 339/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | LOXL2 1421/4885CYP1A2 133/4885CYP3A4 52/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | LOXL2 1421/4885CYP1A2 133/4885CYP3A4 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.